You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Chlorpheniramine maleate; phenylpropanolamine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for chlorpheniramine maleate; phenylpropanolamine hydrochloride and what is the scope of patent protection?

Chlorpheniramine maleate; phenylpropanolamine hydrochloride is the generic ingredient in three branded drugs marketed by Graham Dm and Novartis, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for chlorpheniramine maleate; phenylpropanolamine hydrochloride
US Patents:0
Tradenames:3
Applicants:2
NDAs:3
DailyMed Link:chlorpheniramine maleate; phenylpropanolamine hydrochloride at DailyMed

US Patents and Regulatory Information for chlorpheniramine maleate; phenylpropanolamine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Graham Dm COLD CAPSULE V chlorpheniramine maleate; phenylpropanolamine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 018794-001 Apr 23, 1985 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Graham Dm COLD CAPSULE IV chlorpheniramine maleate; phenylpropanolamine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 018793-001 Apr 25, 1985 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Novartis TRIAMINIC-12 chlorpheniramine maleate; phenylpropanolamine hydrochloride TABLET, EXTENDED RELEASE;ORAL 018115-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Chlorpheniramine maleate; phenylpropanolamine hydrochloride Market Analysis and Financial Projection Experimental

Chlorpheniramine Maleate and Phenylpropanolamine Hydrochloride: Market Dynamics and Financial Trajectory

Introduction

Chlorpheniramine maleate and phenylpropanolamine hydrochloride are medications commonly used to treat various allergic conditions. This article delves into the market dynamics, financial trajectory, and key factors influencing the demand for these drugs.

Chlorpheniramine Maleate Market Overview

Global Market Size and Growth

The global chlorpheniramine maleate market was valued at USD 518.02 million in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.9% from 2023 to 2032, reaching USD 751.4 million by 2032[4].

Regional Market Performance

  • North America: This region holds the majority share of the global market, with a market size of USD 207.28 million in 2023. It is expected to grow at a CAGR of 3.2% from 2023 to 2031, driven by advanced healthcare infrastructure and an increase in allergic conditions[1].
  • Europe: Europe also constitutes a significant portion of the market, with a market size of USD 155.46 million in 2023. The region's well-established healthcare system and high awareness of allergy management contribute to its growth[1].
  • Asia-Pacific: This region is expected to witness the highest growth rate, with a CAGR of 5.5% from 2023 to 2032. Factors such as rising prevalence of allergic conditions, increasing consumer awareness, and growing geriatric population drive this growth[4].
  • Latin America and Middle East & Africa: These regions, though smaller, are also experiencing growth due to improving healthcare infrastructure and increasing knowledge of allergy management, with CAGRs of 4.4% and 4.7%, respectively[1].

Phenylpropanolamine Hydrochloride Market Dynamics

Historical Context and Current Status

Phenylpropanolamine hydrochloride, once used in nasal decongestants and weight loss products, has been withdrawn from the market in the United States and Canada due to safety concerns, particularly the risk of hemorrhagic strokes[2][5].

Impact on the Market

The withdrawal of phenylpropanolamine hydrochloride has shifted market focus towards safer alternatives like chlorpheniramine maleate. This shift has contributed to the growth of the chlorpheniramine maleate market as consumers and healthcare providers seek reliable and safe treatments for allergic conditions.

Key Drivers of the Chlorpheniramine Maleate Market

Increasing Prevalence of Allergic Conditions

The rise in allergic disorders such as allergic rhinitis, hay fever, and other respiratory allergies is a significant driver. This increase is attributed to factors like urbanization, changing lifestyles, and rising air pollution[4].

Advancements in Healthcare Infrastructure

Regions with well-developed healthcare systems, such as North America and Europe, see higher demand for chlorpheniramine maleate due to easy access to healthcare services and over-the-counter (OTC) medications[1][4].

Consumer Awareness and Geriatric Population

Increased consumer awareness about allergy management and the growing geriatric population, which is more prone to allergic conditions, also drive the market growth[4].

Challenges and Restraints

Availability of Alternative Medications

The presence of alternative medications for treating allergies can hamper the growth of the chlorpheniramine maleate market. Consumers may opt for other antihistamines or treatments based on personal preferences or healthcare provider recommendations[4].

Potential Side Effects

Chlorpheniramine maleate can have side effects such as drowsiness, dry mouth, blurred vision, and urinary retention, which may deter some consumers and impact market growth[4].

Competitive Landscape

Key Market Players

The chlorpheniramine maleate market is dominated by companies such as Capellon Pharmaceuticals, GlaxoSmithKline plc, Viatris Inc., Johnson & Johnson, Sun Pharmaceutical Industries Limited, and others. These companies play a crucial role in manufacturing and distributing chlorpheniramine maleate products globally[4].

Financial Trajectory

Revenue Projections

The global chlorpheniramine maleate market is expected to grow significantly, reaching USD 751.4 million by 2032 from USD 468.6 million in 2022. This growth is driven by the increasing demand for antihistamines and the expanding healthcare infrastructure in various regions[4].

Regional Revenue Contributions

North America will continue to dominate the market, followed by Europe. The Asia-Pacific region, however, will experience the highest growth rate due to its large population and increasing awareness of allergy management[1][4].

Impact of COVID-19

Positive Impact

The COVID-19 pandemic has had a positive impact on the chlorpheniramine maleate market. The increased focus on healthcare and the rise in respiratory ailments during the pandemic have boosted the demand for antihistamines and other allergy medications[4].

Conclusion

The chlorpheniramine maleate market is poised for steady growth driven by increasing allergic conditions, advancements in healthcare infrastructure, and rising consumer awareness. While the withdrawal of phenylpropanolamine hydrochloride has shifted market focus towards safer alternatives, the chlorpheniramine maleate market remains robust with significant revenue projections.

Key Takeaways

  • The global chlorpheniramine maleate market is projected to reach USD 751.4 million by 2032.
  • North America dominates the market, but the Asia-Pacific region will experience the highest growth rate.
  • Increasing prevalence of allergic conditions and advancements in healthcare infrastructure are key drivers.
  • Potential side effects and availability of alternative medications are restraints.
  • The COVID-19 pandemic has positively impacted the market.

FAQs

What is chlorpheniramine maleate used for?

Chlorpheniramine maleate is an antiallergic medicine used to treat various allergic conditions such as allergic rhinitis, hay fever, and symptoms like sneezing, itchy nose or throat, and runny nose caused by allergies and the common cold[4].

Why was phenylpropanolamine hydrochloride withdrawn from the market?

Phenylpropanolamine hydrochloride was withdrawn due to the risk of hemorrhagic strokes associated with its use[2][5].

What regions are expected to drive the growth of the chlorpheniramine maleate market?

North America and the Asia-Pacific region are expected to be the key drivers, with the Asia-Pacific region witnessing the highest growth rate[1][4].

What are the potential side effects of chlorpheniramine maleate?

Potential side effects include drowsiness, dry mouth, blurred vision, and urinary retention[4].

How has the COVID-19 pandemic impacted the chlorpheniramine maleate market?

The pandemic has had a positive impact on the market due to increased focus on healthcare and the rise in respiratory ailments[4].

Sources

  1. Cognitive Market Research - Global Chlorpheniramine Maleate Market Report.
  2. DrugBank - Phenylpropanolamine: Uses, Interactions, Mechanism of Action.
  3. Allied Market Research - Chlorpheniramine Maleate Market | $751.4 Million by 2032.
  4. Allied Market Research - Chlorpheniramine Maleate Market Statistics and Forecast - 2032.
  5. Drugs.com - Chlorpheniramine and Phenylpropanolamine Uses, Side Effects.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.